Evogene reports Q2 EPS ($1.68) vs. ($5.20) last year

Reports Q2 revenue $0.9M vs. $0.7M last year. CEO Ofer Haviv stated: “…During the past years we developed three innovative AI tech-engines addressing the main development challenges of products rooted in microbes, small molecules and genomics. Our AI tech-engines were structured to be compatible with the tremendous potential of various market segments and not limited to only one specific segment…Today, Evogene has 4 subsidiaries, each focusing on a different market segment, and in addition, Evogene has diverse engagements with leading companies in additional market segments, not covered by our subsidiaries.”